retatrutide clinical trial data Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide Starting Dose: What Clinical

Toward a broader response to cardiometabolic disease

Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) in Phase 2/3 trials

The American Association for the Study of Liver Diseases (AASLD) acknowledges the potential role of GLP-1 receptor agonists in managing MASLD, particularly in patients with concurrent type 2 diabetes or obesity

It tends to peak in the first few days after injection and usually becomes more bearable as your body adjusts to the medication

Despite widespread demand, affordability and insurance coverage lag far behind medical efficacy

Extensive safety and efficacy data exist